I was wondering about AVX patent life on ATC and stumbled on this article by Marc Sinatra:
http://www.biotechdaily.com.au/media/sinatra/BD%20Biotech%20Daily%20Avexa%20Mar%2028%202011.pdf
So if we don't get the patent extension we filed last year on the 23/11/11, it means the patents expire in 2013 when we may go to market? This could be an issue in getting partnering with big pharma IMO. Big pharma may be waiting til this is finalised before signing (similar perhaps to Anteo and eBioscience).
Thoughts?
Add to My Watchlist
What is My Watchlist?